Cytomedix, Inc. is a biotechnology company that develops, sells, and licenses advanced tissue regeneration technologies to primarily address the areas of wound care, inflammation, and angiogenesis. The company focuses on autologous stem cells, platelet-derived signal molecules and plasma scaffolds. The Company markets the AutoloGel System, a device for the production of autologous platelet rich plasma gel for use on a variety of exuding wounds, the Angel Whole Blood Separation System, a blood processing device, and other disposable products. On February 8, 2012 Cytomedix closed the acquisition of Aldagen, a biopharmaceutical company developing regenerative cell therapies based on its proprietary ALDH bright cell ("ALDHbr") technology, currently in a Phase 2 trial for the treatment of ischemic stroke.

Acquired Companies: Aldagen, Inc.